Fang 2020.

Methods	Study design: Randomised clinical trial Study duration: August 2017 to November 2019 Duration of follow‐up: 2 years Setting: Hospital
Participants	Number of participants: 50 Inclusion criteria: Diagnosed as HCC; Child‐Pugh Class A or B; large or huge tumour Age (mean ± SD, range ): TACE + MWA: 55.10 ± 5.32 years; TACE alone: 54.26 ± 5.09 years Male (n/total): TACE + MWA: 15/25; TACE alone: 16/25
Interventions	TACE + MWA group (n = 25): TACE: TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: epirubicin 20–50 mg and oxaliplatin 50–150 mg MWA: The interval between TACE and MWA was 14 days. Control group (n = 25): TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: epirubicin 20–50 mg and oxaliplatin 50–150 mg
Outcomes	Tumour response: measured by contrast‐enhanced CT at 6 months after treatment Survival rates: measured at 1 and 2 years after treatment Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.